MARKET WIREYahoo Finance UK • 21h ago
Royalty Pharma plc (RPRX) stock price, news, quote and historyYahoo Finance UK report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
Why RPRX Stock slipped -0.98% Today — RQD Quant Desk Flash
$66.52 -0.98% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $66.56
Royalty Pharma plc (Class A) (RPRX) earns a Roarable Rating of B+ (Buy) with 76/100 RQD Confidence. High-quality cash engine (steady margins, 7% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B+ • BUY
Cap $38.63B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on RPRX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is RPRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Royalty Pharma plc (Class A) (NASDAQ: RPRX) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $66.52 (-0.98% 1D, market cap $38.63B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 19/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 14/20. Across 1015 tracked Health Care issuers, RPRX ranks #28 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does RPRX compare to GMAB and ONC in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RPRX carries a Roarable B+ (76/100 RQD), trailing P/E of 49.2x, gross margin of —, and ROIC of 7.0%. By comparison, GMAB (Genmab A/S ADS) holds a B- grade (70/100 RQD, P/E 32.8x, ROIC 9.9%, cap $35.61B) and ONC (BeOne Medicines Ltd.) posts a B- grade (71/100 RQD, P/E 147.2x, ROIC 10.5%, cap $42.11B). Among the 5-stock peer group, ZTS leads on earnings multiple (12.2x) while ZTS leads on capital efficiency (25.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for RPRX?
▼
Per RPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802768), Royalty Pharma plc (Class A) generated $2.38B in revenue (+5.1% YoY), $770.9M in net income, and $2.38B in free cash flow against $19.62B in total assets and $8.57B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 49x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $66.56 (+0.06%)🧬 Cannibal Buyback (-1.80% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 100.2% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 76/100 (B+) historically ranked in the Top 11% of excess returns over the next 90 days (+7.6% avg 90D alpha vs SPY • 70.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B+
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B+ · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+8.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RPRX)Realized 20D OHLCV Swing Band: ±4.8%
Deterministic 5-Pillar Attribution (76/100 Composite)
🔍 WHY RPRX SCORES 76/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+19/20 pts (25% of score)
20D Institutional Volume Accumulation (±4.8% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+16/20 pts (21% of score)
FRED Regime × Technicals: 96% of 52W Range • RSI-14 at 72 (OVERBOUGHT (>70))
▼ #1 Drag / Risk Factor: Cash Engine Quality13/20 pts (-7 pt drag)
Capital intensity & 52% operating margin leave 7 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$58.99+5.4% Next Q
68
Q2 (-2Q)Grade B$62.15+4.3% Next Q
71
Q3 (-1Q)Grade B$64.82+2.6% Next Q
73
CurrentGrade B+$66.52+7.6% Hist 90D α
76
Trajectory: B- (68) → B+ (76)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the RPRX Bull Thesis Could Fail
Even with a 76/100 (B+) score, RPRX faces multiple-compression risk if 49.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Priced at 49x earnings—high expectations leave less room for a lukewarm quarter.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($60.56) or 200D SMA ($53.63) invalidates the momentum regime and cuts Target Base ($71.91) toward Bear Floor ($54.55).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $RPRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RPRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why RPRX Stock slipped -0.98% Today — RQD Quant Desk Flash
Royalty Pharma plc (Class A) (RPRX) slipped -0.98% to $66.52, trading at 96% of its 52-week range ($36.03 – $67.71). High-quality cash engine (steady margins, 7% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 96% of its 52-week range ($36.03 – $67.71) with RSI-14 at 72 (OVERBOUGHT (>70)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±4.8% around $66.52 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B+ (Buy) backed by 52% gross margin and $2.4B annual free cash flow.
Live RPRX Headlines & Catalysts
MARKET WIREThe Motley Fool • 1d ago
Should You Buy Royalty Pharma Stock Before Nov. 4?The Motley Fool report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Royalty Pharma (Nasdaq:RPRX) - Stock AnalysisSimply Wall St report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Royalty Pharma plc (RPRX) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much TodayBenzinga report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
CATALYSTMarketBeat • 1d ago
Royalty Pharma (NASDAQ:RPRX) Stock Jumps 3.3% - Here's WhyMarketBeat report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Royalty Pharma (RPRX), Why Is It Back In The Spotlight?Simply Wall St report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 3d ago
Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision NearsZenas BioPharma (NASDAQ:ZBIO) outlined development plans for obexelimab in systemic lupus erythematosus (SLE) and ZB021, an investigational oral IL-17AA/AF inhibitor, during an R&D event ahead of clinical data expected l
MARKET WIREYahoo • 4d ago
Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key MetricsBeyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended Septemb
CATALYSTYahoo • 5d ago
Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseGuardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (RPRX Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
RPRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +32.51%⚡ TESTING RESISTANCE
2026-11-03O $65.93H $67.18L $65.93C $66.52VOL 4.66M
RES: $67.97SUP: $54.62SMA50: $60.56SMA200: $53.63
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
RPRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
35.9%/yr Implied 5Y Growth
vs. +5.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on RPRX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for RPRX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RPRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RPRX)
Health Care Rank #28 of 1015
⚔️ GMAB vs RPRX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (RPRX vs. GMAB, ONC, ZTS, TEVA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Royalty Pharma plc (Class A) (RPRX) ranks #28 by composite RQD confidence (76/100, grade B+) and #46 by equity capitalization ($38.63B). Within this direct 5-issuer industry benchmark cohort, ZTS leads on earnings valuation at 12.2x trailing P/E, while ZTS leads on capital efficiency and profitability with 25.7% ROIC and 71.8% gross margin. RPRX currently leads its immediate peer cohort in composite quantitative strength at 76/100 (B+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RPRX
ACTIVE
Royalty Pharma plc (Class A) | B+ | 76/100 | 49.2x | — | 7.0% | -0.98% | $38.63B | Benchmark Subject |
| GMAB Genmab A/S ADS | B- | 70/100 | 32.8x | — | 9.9% | -3.75% | $35.61B | /gmab-vs-rprx → |
| ONC BeOne Medicines Ltd. | B- | 71/100 | 147.2x | 87.5% | 10.5% | -2.45% | $42.11B | /onc-vs-rprx → |
| ZTS Zoetis Inc. | C+ | 68/100 | 12.2x | 71.8% | 25.7% | +4.34% | $32.94B | /zts-vs-rprx → |
| TEVA Teva Pharmaceutical Industries Limited | C- | 61/100 | 34.3x | 51.8% | 9.4% | -3.30% | $49.05B | /teva-vs-rprx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001802768 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Royalty Pharma plc (Class A) (RPRX) reported GAAP revenue of $2.38B (+5.1% vs. FY2024 revenue of $2.26B , and +1.0% cumulative change since FY2023) , GAAP net income of $770.9M, operating cash flow of $2.49B, and free cash flow of $2.38B (-10.7% YoY). On the balance sheet, RPRX closed FY2025 with $19.62B in total assets against $8.57B in total debt (Altman Z-Score: 2.90, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.38B | $770.9M | $2.49B | $2.38B | $19.62B | $8.57B |
| FY2024 (FY) | 2024-12-31 | $2.26B | $859.0M | $2.77B | $2.67B | $18.22B | $6.61B |
| FY2023 (FY) | 2023-12-31 | $2.35B | $1.13B | $2.99B | $2.88B | $20.85B | $4.88B |
3. RPRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs RPRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Royalty Pharma plc (Class A) (NASDAQ: RPRX) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $66.52 (-0.98% 1D, market cap $38.63B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 19/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 14/20. Across 1015 tracked Health Care issuers, RPRX ranks #28 in composite RQD confidence.
How does RPRX compare to GMAB and ONC in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RPRX carries a Roarable B+ (76/100 RQD), trailing P/E of 49.2x, gross margin of —, and ROIC of 7.0%. By comparison, GMAB (Genmab A/S ADS) holds a B- grade (70/100 RQD, P/E 32.8x, ROIC 9.9%, cap $35.61B) and ONC (BeOne Medicines Ltd.) posts a B- grade (71/100 RQD, P/E 147.2x, ROIC 10.5%, cap $42.11B). Among the 5-stock peer group, ZTS leads on earnings multiple (12.2x) while ZTS leads on capital efficiency (25.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for RPRX?
Per RPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802768), Royalty Pharma plc (Class A) generated $2.38B in revenue (+5.1% YoY), $770.9M in net income, and $2.38B in free cash flow against $19.62B in total assets and $8.57B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 49x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.
Where is RPRX trading relative to its 50-day, 200-day, and 52-week technical levels?
RPRX last traded at $66.52 (-0.98% on volume of 2,873,558 shares), positioning the stock +9.84% above its 50-day simple moving average ($60.56) and +24.04% above its 200-day simple moving average ($53.63). Across its 52-week range of $36.03 to $67.71, RPRX sits at the 96.2% percentile with a 14-day RSI of 72.0 (OVERBOUGHT (>70)) and an implied next-earnings move of ±4.8% ($63.33 to $69.71).
ROARABLE RATING BRIEF • RQD 76/100 (B+)
✓ SEC XBRL & RQD VERIFIED
RPRX — Royalty Pharma plc (Class A): What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Royalty Pharma plc (Class A) (RPRX) earns a live Roarable RQD composite score of 76/100, corresponding to a B+ letter grade (Roarable Buy) at a spot price of $66.52 (-0.98% 1D, market capitalization $38.63B).
- Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of 7.0%, gross margin of —, operating margin of 65.6%, and free cash flow yield of 6.29%.
- Whale 13F & Options Flow (19/20) + Insider Conviction (14/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (16/20) + Forensic Balance Sheet (14/20): Incorporates a 0.94x equity beta, Altman Z-Score of 2.90, Piotroski F-Score of 8/9, and Debt/Equity of 0.88x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Royalty Pharma plc (Class A Ordinary Shares, NASDAQ: RPRX) is classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. It is a publicly traded US issuer with a market capitalization of $37.9B. Operating margin of 65.6% and net margin of 32.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Royalty Pharma plc (Class A) (RPRX) reported $2.38B in annual revenue (up from $2.26B in FY2024, +5.1% YoY) and $770.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.35B revenue, $1.13B net income) through FY2025, RPRX scaled operating cash flow to $2.49B and free cash flow to $2.38B, backed by $19.62B in total assets against $8.57B in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (B+ • RQD 76/100): Big institutional funds and options desks are actively positioning on the bullish side. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 19/20, sustained execution supports upside toward the upper end of the $36.03 – $67.71 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Priced at 49x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 49.2x trailing P/E and 27.8x EV/EBITDA against 65.6% operating margins and a 0.94x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Supply_chain is NONE and butterfly_links is empty. The graph does not identify upstream or downstream dependencies, sector correlations beyond the stated sector and industry, or second-order bottlenecks. A prospective investor should not infer supply-chain relationships from this data.
- Key Question #1: Can RPRX sustain or expand its 65.6% operating margin and 7.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $2.38B and free cash flow of $2.38B, how will capital allocation balance growth reinvestment against $8.57B in total debt?
- Key Question #3: How sensitive is RPRX's 45.8x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.94x)?
RPRX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Royalty Pharma plc (Class A) (RPRX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance UK • 21h ago
Royalty Pharma plc (RPRX) stock price, news, quote and history Yahoo Finance UK report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Motley Fool • 1d ago
Should You Buy Royalty Pharma Stock Before Nov. 4? The Motley Fool report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Royalty Pharma (Nasdaq:RPRX) - Stock Analysis Simply Wall St report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Royalty Pharma plc (RPRX) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today Benzinga report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST MarketBeat • 1d ago
Royalty Pharma (NASDAQ:RPRX) Stock Jumps 3.3% - Here's Why MarketBeat report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Royalty Pharma (RPRX), Why Is It Back In The Spotlight? Simply Wall St report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Yahoo • 3d ago
Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears Zenas BioPharma (NASDAQ:ZBIO) outlined development plans for obexelimab in systemic lupus erythematosus (SLE) and ZB021, an investigational oral IL-17AA/AF inhibitor, during an R&D event ahead of clinical data expected l
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
RPRX Bull vs. Bear Conversation Board — What's Your Call at $66.52?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RPRX 🐻 33% BEARISH CONVICTION
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH
🎯 Target: $78.60 (+17.0%)
📌 Pinned Debate Institutional accumulation (18/20 whale-flow pillar) and a strong forensic balance sheet (Piotroski F 8/9, Altman Z 2.9) support the Ro
The street is overcomplicating Royalty Pharma plc (Class A) (RPRX). Institutional accumulation (18/20 whale-flow pillar) and a strong forensic balance sheet (Piotroski F 8/9, Altman Z 2.9) support the Roarable Buy rating.. With an RQD score of 76/100 (B+) and Forensic Balance Sheet at 14/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $72.55.
CapAlloc_Nerd 🐂 BULL
@SkepticalCFA Fair point on 49.2x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH
🎯 Target: $51.73 (-23.0%)
Spot @ $67.18 A P/E (TTM) of 49.2 and ROIC of 7% leave the valuation dependent on sustained cash generation, with net income declining from $1.13B
A P/E (TTM) of 49.2 and ROIC of 7% leave the valuation dependent on sustained cash generation, with net income declining from $1.13B to $770.9M over FY 2023–FY 2025.. Look at the math on RPRX: paying 49.2x trailing P/E for 7.0% ROIC and 65.6% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $59.12 before getting long.